Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the... Read More

Friday December 15, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion... Read More

Tuesday August 8, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, Ampion

Ampio initiates pivotal Ampion osteoarthritis trial

Ampio initiates pivotal Ampion osteoarthritis trial

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it has begun a single injection study to meet the unmet medical need of treating the severe pain and loss of function... Read More

Monday May 1, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Dr. David Bar-Or, Chris Ehrlich, Michael Macaluso

Ampio: FDA discussions continue on best path forward for Ampion

Ampio: FDA discussions continue on best path forward for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it is continuing discussions with the CBER Division of the FDA to determine the best path forward to obtain a Biological... Read More

Thursday November 10, 2016 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA

Ampio Pharmaceuticals announces mostly positive results for Ampion

Ampio Pharmaceuticals announces mostly positive results for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT:AMPE) announced the results of the Ampion PIVOT clinical trial as well as a comprehensive analysis that integrates trial data from three single... Read More

Friday July 1, 2016 0 comments Tags: Englewood, Ampio Pharmaceutical, Ampion, Michael Macaluso

Ampio Pharmaceuticals launches clinical trial of Ampion for treatment of osteoarthritis of the hand

Ampio Pharmaceuticals launches clinical trial of Ampion for treatment of osteoarthritis of the hand

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced patient dosing has begun in the initial clinical trial of Ampion for the treatment of pain due to osteoarthritis of the... Read More

Tuesday May 10, 2016 0 comments Tags: Englewood, Ampio, Ampion, Michael Macaluso, Dr. David Bar-Or

Aytu adds two founders to board of directors

Aytu adds two founders to board of directors

ENGLEWOOD -- Aytu BioScience, Inc .(OTCQX: AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, announced Josh Disbrow , Aytu''s... Read More

Thursday January 28, 2016 0 comments Tags: Aytu BioScience, Josh Disbrow, Jarrett Disbrow, Englewood, Michael Macaluso, MiOXSYS

Ampio opens new headquarters, manufacturing and research facility in Englewood

Ampio opens new headquarters, manufacturing and research facility in Englewood

ENGLEWOOD - Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced the opening of its new headquarters, manufacturing and research facility in Englewood. The facility is located at... Read More

By: InnovatioNews Wednesday July 23, 2014 0 comments Tags: Ampion, Englewood, Michael Macaluso